II. Indications
- Schizophrenia (including acute episodic Agitation)
- Mania
- Bipolar Disorder
- Tourette's Syndrome (not FDA approved)
III. Mechanism
- Primarily a Serotonin 2A Antagonist (Dopamine Antagonist activity is much less)
IV. Class
- Atypical Antipsychotic (Second Generation agent)
V. Dosing
- Oral
- Ziprasidone 20 to 80 mg orally twice daily
-
Parenteral
- Ziprasidone 10 to 20 mg IM
VI. Advantages
- Minimal weight gain than with other Atypical Antipsychotics
- Lower risk of diabetes than with other Atypical Antipsychotics
VII. Drug Interactions
- Increase Antipsychotic levels (toxicity risk): Monitor for toxicity
- Decrease Antipsychotic levels (lower efficacy)
VIII. Adverse Effects
- Lower Extrapyramidal Side Effects compared with other Antipsychotics
- Somnolence (esp. Overdose)
- Nausea
- Weakness
- QTc Prolongation (more than with other Atypical Antipsychotics)
IX. Monitoring
- See Antipsychotics
X. References
- Glauser and Peters (2016) Crit Dec Emerg Med 30(4): 17-27
Images: Related links to external sites (from Bing)
Related Studies
| ziprasidone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ZIPRASIDONE HCL 20 MG CAPSULE | Generic | $0.26 each |
| ZIPRASIDONE HCL 40 MG CAPSULE | Generic | $0.27 each |
| ZIPRASIDONE HCL 60 MG CAPSULE | Generic | $0.36 each |
| ZIPRASIDONE HCL 80 MG CAPSULE | Generic | $0.41 each |